Yantai Dongcheng Pharmaceutical (SHE:002675) subsidiary Xinkesida obtained a radioactive drug manufacturing license from the medical products administrator of China's Shandong province.
The license permits the production of in vivo radioactive lyophilized powder injections at its Yantai facility, with validity until July 14, 2030, according to a Tuesday filing with the Shenzhen bourse.
Shares of the pharmaceutical company closed 2% higher Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments